Author:
Grob J.-J.,Amonkar M.M.,Martin-Algarra S.,Demidov L.V.,Goodman V.,Grotzinger K.,Haney P.,Kämpgen E.,Karaszewska B.,Mauch C.,Miller W.H.,Millward M.,Mirakhur B.,Rutkowski P.,Chiarion-Sileni V.,Swann S.,Hauschild A.
Funder
GlaxoSmithKline. All authors listed meet the criteria for authorship set forth by the International Committee for Medical Journal Editors
Reference26 articles.
1. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase no. 10 (Updated December 2010);Ferlay,2010
2. Malignant melanoma: the implications of cost for stakeholder innovation;Styperek;Am J Pharm Benefits,2012
3. Mutations of the BRAF gene in human cancer;Davies;Nature,2002
4. Distinct sets of genetic alterations in melanoma;Curtin;N Engl J Med,2005
5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献